Efficacy and Safety Evaluation of ITI-1284 Monotherapy in Generalized Anxiety Disorder Patients with Inadequate Response to Standard Treatment

The primary objective of this study is to evaluate the **efficacy** of two doses of ITI-1284 (10 mg and 20 mg) administered once daily as monotherapy compared with placebo in patients with **Generalized Anxiety Disorder** (GAD) who have had an inadequate response to previous GAD treatment. This is measured by the change from baseline to the end of Week 6 in the Hamilton Anxiety Rating Scale (HAM-A) total score. The clinical relevance of this objective lies in its potential to provide an effective treatment option for patients with GAD who do not respond adequately to existing therapies, thereby addressing a significant unmet medical need.

The secondary objective is to assess the efficacy of the same doses of ITI-1284 compared with placebo, as measured by the change from baseline to the end of Week 6 in the Clinical Global Impression-Severity (CGI-S) score. This secondary measure provides additional insight into the overall clinical impact of the treatment on the severity of the disorder.

The clinical trial involves a total of **353 participants** diagnosed with **Generalized Anxiety Disorder** (GAD). The study population includes both male and female subjects aged 18 years and older, with a **body mass index (BMI)** ranging from 19 to 40 kg/m². Participants were selected based on their history of inadequate response to at least two approved GAD treatments, such as paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone. All participants are outpatients expected to maintain this status throughout the study. The trial includes individuals who can provide informed consent and are capable of adhering to study instructions. Both genders of childbearing potential are required to use highly effective birth control methods during the study period. The trial population is characterized by a moderate to severe level of anxiety as confirmed by diagnostic criteria and specific rating scales. The study does not exclude vulnerable populations, indicating a broad inclusion of individuals who meet the specified criteria.

The clinical trial is designed as a **randomized, double-blind, placebo-controlled** study to evaluate the efficacy, safety, and tolerability of ITI-1284 as a monotherapy treatment in patients with **Generalized Anxiety Disorder** (GAD) who have had an inadequate response to previous treatments. The trial will involve two doses of ITI-1284, 10 mg and 20 mg, administered once daily, compared with a placebo. The primary efficacy endpoint is the change from baseline to the end of Week 6 in the Hamilton Anxiety Rating Scale (HAM-A) total score. Secondary endpoints include changes in the Clinical Global Impressions-Severity (CGI-S) score and other related measures.

The trial is expected to last approximately six weeks for each participant, with the overall study estimated to conclude by June 2027. Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, body mass index, and diagnostic confirmation of moderate or severe GAD. Following the screening, eligible participants will proceed to the baseline visit, where initial assessments will be conducted.

Throughout the study, participants will attend regular follow-up visits to monitor their response to the treatment and any potential side effects. These visits will include assessments of anxiety symptoms, overall clinical status, and quality of life measures. The end-of-study visit will occur at the conclusion of the six-week treatment period, where final evaluations will be conducted to assess the primary and secondary endpoints.

Participant involvement is expected to last for the duration of the six-week treatment period, with conditions for early termination including significant adverse events, withdrawal of consent, or non-compliance with study procedures. The trial is conducted under strict adherence to ethical guidelines, ensuring that all participants provide informed consent and are monitored closely throughout the study.

The clinical trial involves the administration of **ITI-1284**, a chemical small molecule, as the experimental medication. **ITI-1284** is provided in the form of a **tablet** and is intended for **sublingual use**. The trial evaluates two dosage regimens of **ITI-1284**: 10 mg and 20 mg. The 10 mg dose is administered once daily, with a maximum daily dose of 10 mg and a total maximum dose of 420 mg over a treatment period of 6 weeks. Similarly, the 20 mg dose is also administered once daily, with a maximum daily dose of 20 mg and a total maximum dose of 840 mg over the same treatment period. The active substance, **ITI-1284**, is of chemical origin and is not formulated for pediatric use. The medication is manufactured by Intra-Cellular Therapies, Inc.

The study also includes a **placebo** as a non-experimental treatment to serve as a comparator. The placebo is used to maintain the double-blind nature of the trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments. The placebo is administered in a manner consistent with the experimental medication, although specific details regarding its pharmaceutical form and route of administration are not applicable. The inclusion of a placebo allows for the assessment of the efficacy and safety of **ITI-1284** by comparing outcomes between the active treatment and placebo groups.

The efficacy of ITI-1284 as a monotherapy treatment for patients with **Generalized Anxiety Disorder** (GAD) who have had an inadequate response to previous treatments will be assessed in this clinical trial. The primary efficacy endpoint is the change from baseline to the end of Week 6 in the Hamilton Anxiety Rating Scale (HAM-A) total score. This scale is a widely used and validated tool for measuring the severity of anxiety symptoms. The key secondary efficacy endpoint is the change from baseline to the end of Week 6 in the Clinical Global Impressions-Severity (CGI-S) score. Additional secondary efficacy endpoints include changes from baseline in HAM-A total score, CGI-S score, Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) score, and Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Other secondary endpoints include a ≥50% reduction from baseline in HAM-A total score, HAM-A remission (HAM-A total score ≤7), CGI-Improvement (CGI-I) scale score, and Patient Global Impression of Change (PGI-C) scale score.

Measurements will be collected at baseline and at the end of Week 6, with additional assessments conducted at various visits throughout the study. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, ensuring rigorous evaluation of the treatment's efficacy. The study will compare two doses of ITI-1284 (10 mg and 20 mg) administered once daily against a placebo. The trial will utilize validated scales and patient-reported outcomes to ensure the reliability and accuracy of the efficacy assessments.